Drug-susceptibility patterns of Mycobacterium tuberculosis in Mpumalanga province, South Africa: possible guiding design of retreatment regimen.

AIDS Virus Research Laboratory, Department of Microbiology, University of Venda, South Africa.
Journal of Health Population and Nutrition (Impact Factor: 1.39). 02/2010; 28(1):7-13. DOI: 10.3329/jhpn.v28i1.4518
Source: PubMed

ABSTRACT Multidrug-resistant tuberculosis (MDR-TB) has been a cause of concern in both developed and developing countries. The prevalence of drug resistance in Mycobacterium tuberculosis (MTB) isolates (n=692) from Mpumalanga province was assessed. In total, 692 (64%) MTB strains from cases with pulmonary TB were tested for susceptibility against rifampicin, isoniazid, ethambutol, and streptomycin using the MGIT 960 instrument. Two hundred and nine (30.2%) strains were resistant to one or more drugs. Resistance to one drug ranged from 1.4% for ethambutol to 17.7% for rifampicin. The prevalence of MDR-TB ranged from 6.7% for three drugs to 34% for four drugs, with significant predictors being patients' age-groups of 25-54 years (p=0.0012) and >55 years (p=0.007). The result showed a high level (58.4%) of MDR-TB from cases in Mpumalanga province. To achieve a higher cure rate in this province, drug-susceptibility tests must be done for every case.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT Emergence of multidrug-resistant tuberculosis (MDR-TB) has been a cause of concern in both developed and developing countries. Hence, there is a need for continuous monitoring of drug resistance to anti-tuberculosis drugs in tuberculosis patients. A study was conducted to determine the prevalence anti-TB drug resistance in Mycobacterium tuberculosis isolates obtained from sputum samples of clinically suspected TB patients with no history of previous anti-TB treatment attending a tertiary care hospital from February 2006 to August 2007 in Pune, India. Mycobacterium tuberculosis isolates were subjected to drug susceptibility testing (DST) to four firstline anti-TB drugs namely Isoniazid, Rifampicin, Streptomycin and Ethambutol by Bactec MGIT 960 system being currently used in the Revised National Tuberculosis Control Program (RNTCP). It was found that MDR-TB prevalence in newly diagnosed pulmonary tuberculosis patients in Pune has not increased compared to the earlier data. Adequate data on MDR-TB at national and regional level are not available. Hence, it is essential to conduct nationwide drug resistance surveillance for TB with continuous monitoring of trends to curb the emergence of drug resistance to ensure the success of tuberculosis control programs in the country.
    Int J Pharm Bio Sci. 07/2013; 4(3):579 - 585.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tuberculosis (TB) in both animals and humans is caused by Mycobacterium tuberculosis complex (MTBC) primarily transmitted by inhalation of aerosolized droplets containing the organism. Multi-drug resistance (MDR) and extensive drug resistance (XDR) are evolutionary features of Mycobacterium tuberculosis to subvert the antibiotic regimes in place. The heavy burden of TB worsened by HIV endemic in South Africa motivated for the investigation of MTBC prevalence among TB patients in Port Elizabeth and the amplification and sequencing of the DNA amplicons known to confer resistance to TB drugs.
    BMC Infectious Diseases 09/2014; 14(1):479. · 2.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background & objectives: The emergence of drug resistance tuberculosis (TB) is a significant challenge for TB control and prevention programmes, and the major problem is multidrug resistant tuberculosis (MDR-TB). The present study was carried out to determine the frequency of drug resistant Mycobacterium tuberculosis isolates among newly and retreated TB lymphadenitis patients and risk factors for acquiring this infection. Methods: Two hundred twenty five M. tuberculosis isolates from TB lymphadenitis patients who were diagnosed as new and retreated tuberculosis cases between April 2012 and May 2012 were included in this study. Isolates were tested for susceptibility to isoniazed (INH), rifampicin (RMP), streptomycin (SM), ethambutol (EMB) and pyrazinamide (PZA) using the BacT/AlerT 3D system protocol. Results: Among 225 isolates, 15 (6.7%) were resistant to at least one first line anti-TB drug. Three (1.3%) were MDR-TB. Resistance to INH, RMP, SM, and EMB was found in 8 (3.6%), 4 (1.8%), 10 (4.4%), and 4 (1.8%) isolates, respectively. Of the 212 new TB lymphadenitis cases three (1.4%) were MDR-TB. A rifampicin resistant M. tuberculosis isolate was diagnosed from smear and culture negative newly treated cases. All isolates were susceptible to PZA. Matted cervical lymph nodes were the prominent sites involved. Newly treated TB lymphadenitis patients had a greater risk for presenting resistance to anti-TB drugs ( p =0.046). Interpretation & conclusions: Our study showed that TB lymphadenitis patients harboured drug resistant TB and MDR-TB, although at a low rate. Resistance was not associated with age, sex, patients' education and contact history. Further research is required to determine transmission dynamics of drug resistant strains.
    The Indian journal of medical research. 07/2014; 140(1):116-122.

Full-text (2 Sources)

Available from
May 16, 2014